期刊
EXPERT REVIEW OF HEMATOLOGY
卷 14, 期 6, 页码 547-559出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474086.2021.1935851
关键词
Hodgkin lymphoma; immunodeficiency-associated Hodgkin lymphoma; HIV-associated Hodgkin lymphoma; post-transplant-associated Hodgkin lymphoma; tumor microenvironment; management
类别
资金
- Centro di Riferimento Oncologico, Aviano
- Italian Ministry of Health
HL can occur in different host conditions, such as the general population and immunocompromised individuals like PLWH. Current treatment strategies for HIV-associated HL include the combination of cART with anti-neoplastic treatments and high-dose chemotherapy, which have shown to improve long-term survival rates for patients. Immune checkpoint inhibitors are also being explored as a potential treatment option for relapsed and refractory HL cases in the general population.
Introduction: Hodgkin lymphoma (HL) can occur in different host conditions, i.e. in the general population and immunocompromised individuals, either during HIV infection or solid organ/hematopoietic transplantation and immunosuppressive drug treatment. Areas covered: Areas covered include multidimensional characteristics of tumor cells and cellular composition of tumor microenvironment of HL. Current conventional treatments and new treatment strategies for HL in immunosuppressed patients, especially in persons living with HIV (PLWH), are also discussed. PubMed and MEDLINE were used for database searches to identify articles in English published from 1989 to 2020. Expert opinion: For people with post-transplant HL or for those with HIV/AIDS-associated HL, standard treatments mirror those in the general population. In the last decade, the combination of cART with anti-neoplastic treatments, alongside with current anti-rejection therapies, has increased long-term survival of people with HL and acquired immune deficiencies. High-dose chemotherapy and autologous stem cell transplantation have been favorably proven as salvage therapy in PLWH with relapsed and refractory HL. Immune checkpoint inhibitors emerged as an area of clinical investigation for relapsed and refractory HL in the general population. Pembrolizumab, an anti-programmed cell death protein 1 (PD-1) drug, resulted safe in PLWH indicating that PD-1 ligand assessment should be advisable in HIV-associated HL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据